The detection of oligometastatic adrenal metastases is increasing and there are limited data supporting the use of curative intent stereotactic body radiation therapy (SBRT) to treat patients with limited metastatic disease with adrenal involvement. Therefore, we utilized a prospectively maintained database of consecutive patients treated with SBRT for limited metastatic disease (5 sites) to identify patients with adrenal metastases. Patients were either treated on a three-fraction dose escalation protocol or a ten fraction off-protocol regimen.
Introduction
The adrenal gland is a common site of metastasis from melanoma, breast, lung, renal, and gastrointestinal malignancies, among others. In autopsy series, the incidence of adrenal metastases ranges from 31-54% for breast cancer, 18-38% for lung cancer, 3-21% for gastrointestinal malignancies, and 20-24% for renal cell carcinoma (1) . Previously, adrenal metastases were detected when they became bulky and resulted in local symptoms. With increasing imaging surveillance of cancer patients, the incidence of asymptomatic adrenal metastases is rising (2) .
Treatments for adrenal metastases and otherwise limited metastatic disease were previously limited to adrenalectomy, radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), or systemic therapy (3, 4) . In a metaanalysis of 114 patients with non-small cell lung cancer undergoing resection of adrenal metastases, the 5-year overall survival was 25-26%, suggesting that there can be long-term survivors in this group of patients (5) . While surgery may improve outcomes, there are associated complications, including infections (3.8-12%), myocardial infarction (2%), ileus (7%), and even death (2%) (3, 5) . In addition to complications of surgery, many patients with metastatic disease have other comorbidities that may make them medically inoperable or have metastases that are technically unresectable. Therefore, non-invasive techniques, such as SBRT may provide a more tolerable treatment option.
At our institution, based on data from patients achieving prolonged disease-free intervals and survival times when metastatic sites are treated definitively (6, 7) , we have routinely offered SBRT to patients with limited metastatic disease, defined as 5 metastases. Previous reports from our group have demonstrated that patients may benefit from aggressive radiotherapy to all known metastases, consistent with the oligometastasis hypothesis (8, 9) . To date, there are limited data supporting the use of curative intent stereotactic body radiation therapy (SBRT) to treat patients with oligometastatic disease with adrenal involvement. In this report, we present our experience using SBRT to treat patients with curative intent to adrenal metastases and summarize the existing literature.
Materials and Methods

Patient Population
A prospectively maintained database of consecutive patients treated with SBRT for limited metastatic disease (5 sites) was reviewed. Patients receiving SBRT to adrenal metastases, from any primary tumor site, with curative intent were identified and constituted the study population for this case series. This study was approved by the University of Chicago Institutional Review Board.
Treatment
SBRT Technique: All patients underwent CT-based treatment planning in custom-made immobilization devices. Patients underwent a series of CT scans, including a freebreathing CT scan, an end-expiratory gated scan, and a 4-dimensional CT scan to assess for respiratory motion. The gross tumor volume was contoured on axial CT images, and PET scans, if available, were anatomically registered to the planning CT scans to modify the target volume. An internal target volume (ITV) was delineated with the use of maximal intensity projection (MIP) images from a 4-dimensional CT scan. MIP images from the entire respiratory cycle were used when there was not significant tumor motion or from the end-expiratory phase if there was significant tumor motion. The planning target volume (PTV) included the ITV plus an additional 5-10 mm margin to account for setup error and organ motion. There was no expansion to account for microscopic spread of the disease.
Non-opposed axial and non-coplanar fields were designed to achieve a steep dose gradient between the target volume and the surrounding uninvolved organs. Some patients were treated on an institutional three-fraction Phase I dose-escalation protocol with a starting dose of 24 Gy in 8 Gy fractions escalated to 42 Gy in 14 Gy fractions. Patients on protocol were treated with a minimum separation of 48 hours and a maximum of 192 hours. Patients treated off-protocol underwent similar radiation planning techniques; however, these patients were treated with a ten fraction regimen based on previously published series (10, 11) . Radiation dose was prescribed to the PTV edge, typically to the 80-90% isodose line, with 95% of the PTV required to receive 95% of the planned dose. Tissue heterogeneity corrections were always employed.
Prior to each treatment, kilovoltage (kV) orthogonal images were acquired and correlated with bony anatomy. A nongated kV cone beam CT scan was then acquired to visualize the target and confirm that it was encompassed by the PTV. All imaging was reviewed prior to each treatment by a single attending physician (JKS). Most patients were pretreated with anti-emetics, and analgesics as needed. Patients treated on the three fraction regimen were assessed by the attending physician for acute toxicity following each treatment, and those treated with a ten fraction regimen were assessed weekly. Acute and late toxicity were scored via the Common Terminology Criteria for Adverse Events version 3.0 (12).
Systemic Therapy:
Most patients received systemic chemotherapy for metastatic disease prior to adrenal SBRT, which was determined by the treating medical oncologist. No patients received chemotherapy concurrently with the radiation therapy.
Follow-up & Response Evaluation
Patients were evaluated 2-4 weeks after the completion of SBRT, then monthly for two additional visits, and then every three months until disease progression or death. At each visit, a comprehensive history and physical examination was performed, as well as serum chemistries to assess for electrolyte abnormalities. Additionally, all patients underwent assessment with imaging (CT with or without a PET scan) one month after treatment and every three months thereafter.
Response to SBRT was determined by Response Evaluation
Criteria in Solid Tumors (RECIST) criteria v.1.1 (13). Patterns of first and cumulative progression were determined by following all treated metastases, primary tumors, and new metastases on all follow-up imaging studies.
Statistical Analysis
Patient-based and treated-metastasis-based analyses were performed. For the patient-based analysis, the following Technology in Cancer Research & Treatment, Volume 12, Number 3, June 2013 endpoints were evaluated: freedom from chemotherapy, defined as the time from end of treatment to initiation of further chemotherapy; distant control (DC), defined as time to progression outside of treated metastases; and overall survival (OS). Analysis by treated-metastasis was primarily used to establish the rate of treated-metastasis control (TMC), defined as response or stable disease in the treatedmetastasis treated with SBRT according to the RECIST criteria. Estimates of probability of freedom from chemotherapy, DC, OS, and TMC were calculated using the Kaplan-Meier method. Time to each event was measured from the end of SBRT. Statistical analysis was performed with JMP, Version 9 (SAS, Cary, North Carolina).
Results
Patient Characteristics
Between August 2005 and June 2009, 10 patients with 13 adrenal metastases were treated with SBRT. The patient and disease characteristics are listed in Table I . The median age of the patient was 58 (range 43-74) and the median follow-up was 14.9 months (range 5.0-45.8 months). All patients had 5 sites of metastatic disease from either a lung or renal primary at the time of treatment. All patients were diagnosed with adrenal metastases based on imaging characteristics, and one had histologic confirmation of adrenal metastasis at diagnosis. All patients had an ECOG performance status of 2.
Eight of the 10 patients were treated on a dose-escalation protocol administering 3 fractions with 8-14 Gy per fraction. The median dose of radiation delivered to all patients was 36 Gy (range 24 Gy-50 Gy) with a median biologic effective dose (BED 10 ) of 60 Gy (range 43.2-79.2 Gy). Eight of the ten patients also received chemotherapy prior to SBRT with a median of 2 agents. Five of these patients received chemotherapy for metastatic disease and the other 3 patients received chemotherapy as part of treatment of their primary lesion only.
Toxicity
Overall, treatment of adrenal metastases with SBRT was well tolerated. No patients developed Grade 3 or 4 acute toxicity. The most common acute side effect was fatigue (70% grade 1, 10% grade 2). Acute Grade 1 GI toxicity occurred in 30% of patients while 10% of patients developed Grade 2 toxicity. All cases of GI toxicity were nausea. The patient who developed Grade 2 fatigue and GI toxicity was receiving concurrent prophylactic cranial irradiation (PCI). Therefore, the toxicity may have been due to PCI rather than SBRT to the adrenal gland. Adrenal function was assessed in 60% of patients at least once during the entire follow-up period. One patient developed Grade 2 adrenal insufficiency approximately 2.5 years after completion of therapy. This was confounded by his requirement of cortisone injections for control of back pain, but was scored as an SBRT-related toxicity for the purpose of this analysis.
Radiographic Response
The median size of the metastases was 4.1 cm (2.1-7.7cm) and the median initial volume was 19.2 cc (6.4-131.0 cc). At the first follow-up, 4 metastases showed a partial response and 9 were stable. The median time to nadir based on unidimensional measurement was 3. 
Clinical Outcome
Based on analysis by treated metastasis, the 1-year TMC was 73% (Figure 1 ). Three treated metastases progressed; all three were treated at the lowest dose level of the dose-escalation protocol (24 Gy in three fractions, BED 10 5 43.2 Gy). The 10 remaining adrenal metastases were treated at a median BED 10 of 75 Gy (range 60-79.2 Gy), and none progressed. One patient had a PET CR one month after treatment, but the 4 month surveillance PET revealed increased uptake in the treated adrenal gland, suggestive of recurrence. These findings prompted an adrenalectomy in the patient, but the pathologic specimen revealed only brown fat with no evidence of residual or recurrent malignant disease.
Based on analysis by patient, the 1-year DC was 30% ( Figure 2 ). Nine patients (90%) developed new metastases over the course of follow-up. Seven of these patients progressed with new metastases limited in number and location (oligometastatic disease), and five patients received aggressive salvage metastasis-directed therapy with or without subsequent chemotherapy. The two patients who progressed in multiple new sites of disease had small cell lung cancer. The majority of patients required salvage chemotherapy with median time to salvage chemotherapy of 5.3 months (range 1.0-38.8 months) and 1-year freedom from salvage chemotherapy rate of 44%. Two of the 10 patients, salvaged with aggressive metastasis-directed treatment, did not receive systemic chemotherapy after SBRT (follow-up of 5.1 months and 45.8 months). In the entire cohort, the 1 year OS was 90% with a median OS of 17.3 months (Figure 3 ).
Discussion
In this study, we utilize a prospective database of patients with limited metastatic disease treated with curative intent to analyze outcomes in patients treated to adrenal metastases. Overall, the 1-year treated-metastasis control was 73%, distant control was 30%, and overall survival was 90%. Only three treated adrenal metastases progressed but all of these failures were treated to the lowest BED 10 (43.2 Gy) as part of a dose-escalation protocol. We also found that treatment of adrenal metastases with SBRT is well tolerated with the most common toxicity being Grade 1 or 2 fatigue and only one case of suspected late adrenal insufficiency. The majority of patients (90%) developed metastatic disease and eventually required chemotherapy with median time to salvage chemotherapy of 5.3 months. However, two patients never received chemotherapy and underwent local salvage treatments for limited progression. Our outcomes and toxicity rates are similar to other reports in the literature (Table II) . The University of Rochester reported an experience of 30 patients with adrenal metastases treated with hypofractionated radiation therapy with curative (n 5 14) or palliative intent (n 5 16). Doses ranged from 16 Gy in 4 fractions to 50 Gy in 10 fractions. Patients treated with curative intent experienced a median survival of 19 months. In the entire cohort, 1-year overall survival was 44%, 1-year distant control was 13%, and 1-year treatedmetastasis control was 55%. In a study from University of Turin and the Humanitas Cancer Center, 34 patients were treated with hypofractionated doses ranging from 20 Gy in 4 fractions to 45 Gy in 18 fractions (median dose of 32 Gy in 4 fractions) with 1-year and 2-year treated-metastasis control rates of 66% and 32%, respectively, and 2-year OS of 53% (14) . The relatively lower treated-metastasis control rates in these series was likely due to the incorporation of palliative radiotherapy in both of these series (11) . A larger series from the University of Florence reviewed the results of 48 patients with adrenal metastases, with the majority of patients receiving 36 Gy in 3 fractions. The 1-year treated-metastasis control rate was 90% and 1-year OS was 39.7%. There was one case of Grade 2 adrenal insufficiency and no other acute/late toxicities (15) .
The results of these studies also suggest that biologic equivalent dose affects the treated-metastasis control rate. In our series, all 3 patients who progressed in treated metastases received the lowest BED 10 of 43.2 Gy. In a study by Holy et al., 2 of 3 patients with treated-metastasis progression were treated to a low BED 10 (37.5 Gy and 43.2 Gy) (16) . Additionally, the 1-year treated-metastasis control rate from the University of Rochester series was 55%, with 53% of patients treated with palliative regimens (minimum BED 10 5 22.4 Gy, 16 Gy administered in 4 fractions) (11) . In contrast, in the University of Florence study, 83% of the patients were treated with 36 Gy in 3 fractions (BED 10 of 79.2 Gy) and 17% received a single fraction, with progression in only 2 treated adrenal metastases (15) . Additionally, in a Japanese series by Katoh et al., the median BED 10 was 76.8 Gy and there was no adrenal progression (17) . Therefore, it is feasible that the dose used to treat the adrenal metastases was not sufficient in the patients who progressed in our series. Excluding these patients, the median BED 10 was 75 Gy for the 10 metastases that did not progress. Our current practice is to treat oligometastatic adrenal metastases to 50 Gy in 5 Gy fractions (BED 10 of 75 Gy).
Considered together, these studies also show that the predominant pattern of progression is in new metastatic sites. In our series, nine patients (90%) ultimately developed metastases in new sites with 78% of these progressing with limited sites of disease amenable to further metastasis directed therapies. In the University of Florence study (15) , all 48 patients eventually experienced progression in new metastases. In the University of Rochester series (11), 23 of 28 (82%) evaluable patients developed other distant metastases. In the University of Turin and Humanitas Cancer Center study, only 14% of patients were free of distant disease at 2 years. Our study is unique in that it is the first that has reported the number of patients with limited metastatic progression allowing for further metastasis-directed therapy. The predominantly distant failure pattern suggests the need for close surveillance for development of new metastatic sites and the addition of improved systemic agents.
The current analysis is subject to limitations. The sample size is small; although so are many previous reports. Follow-up was also limited, although meaningful, given that most of these patients had metastatic disease and eventually succumbed to their disease. Finally, systemic therapies administered following SBRT could have influenced control of the treated adrenal metastases and may have contributed to the favorable local control observed. The strengths of this study are that the data come from a prospectively collected database and since many of the patients were treated on protocol, their toxicity and further treatment details were recorded carefully.
Despite these limitations, this study contributes to the growing literature supports the safety and effectiveness of SBRT for adrenal metastases. These studies are promising and support conducting a prospective study to further investigate the role of SBRT in these patients.
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